Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Receivables (2016 - 2025)

Regenxbio has reported Receivables over the past 12 years, most recently at $39.6 million for Q4 2025.

  • Quarterly results put Receivables at $39.6 million for Q4 2025, down 3.56% from a year ago — trailing twelve months through Dec 2025 was $39.6 million (down 3.56% YoY), and the annual figure for FY2025 was $39.6 million, down 3.56%.
  • Receivables for Q4 2025 was $39.6 million at Regenxbio, down from $45.1 million in the prior quarter.
  • Over the last five years, Receivables for RGNX hit a ceiling of $77.7 million in Q3 2021 and a floor of $19.4 million in Q1 2025.
  • Median Receivables over the past 5 years was $33.7 million (2021), compared with a mean of $41.4 million.
  • Biggest five-year swings in Receivables: plummeted 66.41% in 2023 and later surged 85.9% in 2025.
  • Regenxbio's Receivables stood at $35.8 million in 2021, then surged by 58.25% to $56.6 million in 2022, then crashed by 46.14% to $30.5 million in 2023, then soared by 34.64% to $41.1 million in 2024, then dropped by 3.56% to $39.6 million in 2025.
  • The last three reported values for Receivables were $39.6 million (Q4 2025), $45.1 million (Q3 2025), and $21.8 million (Q2 2025) per Business Quant data.